Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Orchard Therapeutics plc (ORTX)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 20-F |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | |
| Cost of goods sold | 29.9% | 13.5% | 33.0% | 32.0% | 20.3% | | |
| Gross profit | 70.1% | 86.5% | 67.0% | 68.0% | 79.7% | | |
| Selling, general and administrative | 631.1% | 8470.6% | 2504.3% | 2276.9% | 1510.9% | | |
| Research and development | | | 3611.9% | 4670.2% | 9890.1% | | |
| EBITDA | -777.9% | -8641.9% | -5972.0% | -6812.5% | -11263.6% | | |
| Depreciation | 12.1% | 138.9% | 77.2% | 66.7% | 57.8% | | |
| EBIT | -790.0% | -8780.8% | -6049.2% | -6879.1% | -11321.3% | | |
| Pre-tax income | -675.5% | -8582.4% | -5884.8% | -6592.2% | -11056.1% | | |
| Income taxes | -10.5% | 49.4% | -28.2% | -89.1% | 46.7% | | |
| Net income | -665.0% | -8631.9% | -5856.6% | -6503.1% | -11102.8% | | |
|